Which Score Should Be Used for Risk Stratification of Ischemic Stroke in Patients With Atrial Fibrillation

Which score should be used for risk stratification of ischemic stroke in patients with atrial fibrillation.

is the most important for managing AF. The ACCF/AHA guidelines in the USA,3 the CCS guidelines in Canada,4 and the JCS guidelines in Japan5 recommend using the conventional stroke risk stratification scheme, the CHADS2 (congestive heart failure, hypertension, age >75 years, diabetes mellitus, and stroke [double]) score, for antithrombotic therapy in patients with nonvalvular AF.6 On the other h...

Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1

Different Stroke Scales; Which Scale or Scales Should Be Use?

Background: There has been considerable development in the clinometric of stroke. But, researcher is concerned that some scales are too generic, inherently and the insight may not be provided. The current study was conducted to determine which scale or scales should be used in stroke survivors. Methods: We selected 67 studies which published between January 2010 and December 2018 from Up to d...

Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.

BACKGROUND The rate of stroke in atrial fibrillation (AF) depends on the presence of comorbid conditions and the use of antithrombotic therapy. Although adjusted-dose warfarin is superior to aspirin for reducing stroke in AF, the absolute risk reduction of warfarin depends on the stroke rate with aspirin. This prospective cohort study tested the predictive accuracy of 5 stroke risk stratificati...

The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?

The risk of stroke in patients with non-valvular atrial fibrillation (NVAF) varies widely depending on patient age and the presence of other risk factors such as hypertension, diabetes mellitus, congestive heart failure or prior stroke or transient ischaemic attack (TIA) (1, 2). Warfarin reduces the risk of stroke by about twothirds when compared to placebo or no treatment, and by about two-fif...